Navigation

tavaborole (Kerydin)

 

Classes: Antifungals, Topical

Dosing and uses of Kerydin (tavaborole)

 

Adult dosage forms and strengths

solution

  • 43.5mg/mL (0.5%)

 

Onychomycosis of the Toenail

Indicated for onychomycosis of the toenail(s) due to Trichophyton rubrum or Trichophyton mentagrophytes

Clean and dry nails prior to use; apply to completely cover nail surface and under tip of each nail being treated; allow solution to dry following application

Apply to affected toenails qDay for 48 weeks

 

Pediatric dosage forms and strengths

Safety and efficacy not established

 

Kerydin (tavaborole) adverse (side) effects

1-10%

Application site exfoliation (2.7%)

Ingrown toenail (2.5%)

Application site erythema (1.6%)

Application site dermatitis (1.3%)

 

Warnings

Contraindications

None reported by manufacturer

 

Cautions

Not for oral, ophthalmic, or intravaginal use

Avoid contact with eyes, mouth, vagina, or skin immediately surrounding treated nail; wipe away excess solution from surrounding skin

Product is flammable; avoid use near heat or open flame

 

Pregnancy and lactation

Pregnancy category: C

Use during pregnancy only if benefits outweigh risks

Lactation: Unknown if distributed in human breast milk; use caution

 

Pregnancy categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

 

Pharmacology of Kerydin (tavaborole)

Mechanism of action

An oxaborole antifungal (boron-containing compound); inhibits protein synthesis by inhibition of an aminoacyl-transfer ribonucleic acid (tRNA) synthetase (AARS)

 

Elimination

Excretion: Urine (primarily)